Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | CCR4 | P51679 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 6/20 | 0.44 |
| ▸ | BCDIN3D | Q7Z5W3 | 1/20 | 0.41 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.40 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27228404 | 1.00 | SYK (0.47) | SYKKMT2AKDM4EALDH1A1MAPT | |
| SCHEMBL27228532 | 0.87 | LRRK2 (0.58) | SYKKMT2AKDM4EALDH1A1MAPT | |
| SCHEMBL30914274 | 0.87 | LRRK2 (0.58) | SYKKMT2AKDM4EALDH1A1MAPT | |
| SCHEMBL30860798 | 0.84 | ALK (0.42) | SYKCCR4LRRK2ALK | |
| SCHEMBL27227856 | 0.84 | LRRK2 (0.53) | LRRK2 | |
| SCHEMBL30861063 | 0.84 | LRRK2 (0.53) | LRRK2 | |
| SCHEMBL30860787 | 0.83 | SYK (0.46) | SYKKMT2AKDM4EALDH1A1MAPT | |
| SCHEMBL27227816 | 0.83 | SYK (0.46) | SYKKMT2AKDM4EALDH1A1MAPT | |
| SCHEMBL15585506 | 0.78 | SYK (0.46) | SYKKMT2AKDM4EALDH1A1MAPT | |
| SCHEMBL30860971 | 0.73 | LRRK2 (0.65) | LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240174647-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | NEURON23, INC. | 2024-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240174647-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | LRRK2, MAP3K20, MAP3K5 | SYK 735/4885KMT2A 836/4885KDM4E 1085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.